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Type I diabetes (T1D) results from T cell-mediated damage of pancreatic β-cells and loss 
of insulin production. The cholinergic anti-inflammatory pathway represents a physio-
logical link connecting the central nervous and immune systems via vagus nerve, and 
functions to control the release of proinflammatory cytokines. Using the multiple low-
dose streptozotocin (MLD-STZ) model to induce experimental autoimmune diabetes, 
we investigated the potential of regulating the development of hyperglycemia through 
administration of paraoxon, a highly specific acetylcholinesterase inhibitor (AChEI). We 
demonstrate that pretreatment with paraoxon prevented hyperglycemia in STZ-treated 
C57BL/6 mice. This correlated with a reduction in T cell infiltration into pancreatic islets 
and preservation of the structure and functionality of β-cells. Gene expression analysis of 
pancreatic tissue revealed that increased peripheral cholinergic activity prevented STZ-
mediated loss of insulin production, this being associated with a reduction in IL-1β, IL-6, 
and IL-17 proinflammatory cytokines. Intracellular cytokine analysis in splenic T cells 
demonstrated that inhibition of AChE led to a shift in STZ-induced immune response 
from a predominantly disease-causing IL-17-expressing Th17 cells to IFNγ-positive Th1 
cells. Consistent with this conclusion, inhibition of AChE failed to prevent STZ-induced 
hyperglycemia in IFNγ-deficient mice. Our results provide mechanistic evidence for the 
prevention of murine T1D by inhibition of AChE and suggest a promising strategy for 
modulating disease severity.
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inTrODUcTiOn
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which insulin-producing β cells 
of the pancreatic islets of Langerhans are selectively destroyed. The onset of the hyperglycemia is 
preceded by a preclinical phase of insulitis, characterized by infiltration by T and B lymphocytes, 
myeloid cells, and NK cells into the pancreatic islets. Although the etiology of T1D remains 
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incompletely understood, development of disease is influenced 
by genetic and environmental factors, including viral infections, 
food antigens, toxins, and stress. The autoimmune response is 
initiated in genetically pre-disposed individuals when physi-
ological islet remodeling (1), viral infections, or inflammatory 
cytokines (2) induce the death of β cells. The release of β cell-
specific antigens induces the activation of inflammatory T cells, 
leading to insulitis and, ultimately, β cell destruction. Several 
experimental models have been developed to study T1D, includ-
ing spontaneous [biobreeding rats (BB); non-obese diabetic mice 
(NOD)] and chemically induced disease [multiple low-dose 
streptozotocin (MLD-STZ); alloxan] (3). In the MLD-STZ mouse 
model, many studies have shown that the destruction of β cells 
and development of hyperglycemia resembles the development of 
T1D in humans in being mediated by inflammatory T cells (both 
CD4 and CD8) and regulated by inflammatory cytokines (4–7). 
Moreover, this model has the advantage over the NOD model 
in that it induces only autoimmune diabetes and not any other 
systemic autoimmune disease.
It is well established that the nervous system plays a role in the 
regulation of immune responses and vice versa (8). The capacity 
of the cholinergic system to modulate immune responses has 
been amply demonstrated (9–11). Structurally, it has been shown 
that the major cholinergic parasympathetic nerve, the vagus 
nerve, innervates many organs, including GI tract, pancreas, and 
lymphoid tissues where nerve terminals form synaptic contacts 
with lymphoid cells. Muscarinic and nicotinic acetylcholine 
receptors (AChR) are known to be expressed on many cell types 
of the immune system, including lymphocytes, macrophages, 
and dendritic cells (12–14), suggesting that acetylcholine (ACh) 
may act as a neuroimmunomodulator in interactions between the 
nervous and immune systems. T lymphocytes express muscarinic 
(mAChR) and nicotinic acetylcholine receptors (nAChR) and 
synthesize ACh and acetylcholinesterase (AChE) (10). Functional 
studies have demonstrated that ACh stimulation of T  cells 
through the α7 subunit of nAChR reduces mitogen-induced 
proliferation and secretion of proinflammatory cytokines (15). 
Likewise, activation of α7 nAChR on macrophages inhibits 
the secretion of TNF-α (9). In contrast, stimulation through 
mAChR induces the secretion of proinflammatory cytokines 
(16). These findings gave rise to the concept of the cholinergic 
anti-inflammatory pathway or inflammatory reflex (17), amply 
demonstrated to counteract endotoxemia-induced inflammation 
(18–20). In this reflex pathway, the presence of inflammatory 
molecules in the periphery stimulate the afferent vagus nerve that 
relay the signal to the brain which regulates, through the efferent 
vagus nerve, the production of proinflammatory cytokines (21). 
Our group previously demonstrated that inhibition of AChE 
promotes survival of mice following a lethal oral infection with 
Salmonella, highlighting the physiological significance of this 
pathway in mucosal immunity (11). Furthermore, cholinergic 
stimulation has been shown to decrease the severity of inflamma-
tory conditions, such as experimental autoimmune encephalitis 
(EAE) (15), experimental autoimmune myasthenia gravis (22), 
and Alzheimer’s disease (23).
Several lines of evidence from human studies as well as animal 
models of spontaneous (NOD mice) and chemically induced 
(MLD-STZ) T1D indicate the crucial role played by Th17 cells 
in the pathogenesis of autoimmune diabetes (24–33). In addition 
to IL-17A, the signature cytokine produced by the Th17 lympho-
cyte subset, these cells also secrete a host of other inflammatory 
mediators including IL-17F, IL-21, IL-22, TNFα, GM-CSF, and 
IL-6 (34), which collectively drive the associated immunopa-
thology. In contrast, induction of IFNγ in NOD mice protected 
against diabetes development by suppressing Th17 activity and 
inhibiting IL-17 production (24, 35). Therefore, IL-17 and IFNγ 
appear to play diverse and often cross-regulatory functions dur-
ing the development of T1D. Given the central role of T  cells 
and macrophages in the development of T1D and the existence 
of cholinergic innervation in the pancreas, we investigated the 
potential immunomodulatory effect of AChE inhibition on the 
development of diabetes using the MLD-STZ mouse model. 
Using paraoxon as a systemic AChE inhibitor (11), we demon-
strate that cholinergic activation prevents the development of 
hyperglycemia by inhibiting pancreatic islet inflammation and 
β cell loss. Moreover, inhibition of AChE prevents the differen-
tiation of naïve CD4+ T cells into IL-17-producing Th17 cells 
and, instead, promotes their differentiation to IFNγ-secreting 
Th1 cells. Interestingly, inhibition of AChE fails to modulate 
streptozotozin (STZ)-induced hyperglycemia in IFNγ-deficient 
(IFNγ−/−) mice, demonstrating the crucial role played by IFNγ 
in ACh-mediated inhibition of the autoimmune response against 
islet β cells. Our findings provide a rationale for a new strategy in 
the development of anti-diabetic therapies.
MaTerials anD MeThODs
experimental animals
C57BL/6 mice were purchased from Harlan Olac (Bicester, 
United Kingdom) and bred in the animal facility of the College 
of Medicine and Health Sciences, UAE University. IFNγ−/− mice 
were purchased from Jackson laboratories (USA) and generously 
provided by Dr Mariam Al-Shamsi at our institution. Female mice 
aged 8–10 weeks (weight range 20–22 g) were used for the experi-
ments. All studies involving animals were carried out in accordance 
with, and after approval of, the animal research ethics committee 
of the College of Medicine and Health Sciences, UAE University.
chemicals
Paraoxon (Sigma, St. Louis, MO, USA), an organophosphorous 
compound, is a highly specific, irreversible, inhibitor of AChE 
(11). A stock solution (10  mmol/l) was prepared in acetone. 
Working solution for intraperitoneal (i.p.) injection was prepared 
ex tempore in pyrogen-free saline to a concentration of 80 nmol/
ml. The final acetone concentration in the paraxon solution used 
for i.p. injection was ~108 μM. Each mouse received 40 nmol/day 
of paraoxon or saline in 0.5 ml volume. STZ (Sigma) was prepared 
ex tempore in citrate buffer (pH 4.5) and used i.p. at 60 mg/kg/day 
per mouse, unless otherwise indicated.
Diabetes induction
To induce autoimmune diabetes, the MLD-STZ model was used 
(3). C57BL/6 and IFNγ−/− mice were administered five consecutive 
TaBle 1 | list of primers.
gene Taqman gene iD/sequence
IL-1β Mm00434228-m1
IL-6 Mm00446190-m1
IL-12p40 Mm00434174-m1
IL-17F Mm00521423-m1
IFN-γ Mm01168134-m1
Insulin Mm00731595-gh
TNFα (Metabion) F: 5′-CCT CCC TCT CAT CAG TTC TAT-3′
R: 5′-CTA GTT GGT TGT CTT TGA GAT CC-3′
Probe: 5′-6-Fam-ACA AGC CTG TAG CCC ACG TCG 
TAG-BHQ-1-3′
IL-23p19 (Metabion) F: 5′-CATGCTAGCCTGGAACG-3′
R: 5′-GATCCTTTGCAAGCAGAA-3′
Probe: 5′-6-Fam-TGACCCACAAGGACTCAAGGACA 
BHQ-1-3′
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daily doses of STZ; control mice received citrate buffer. At differ-
ent time points post-STZ administration, blood was drawn from 
the tail vein to determine glucose levels using One-Touch-ultra-
strip (Lifescan, Zurich, Switzerland). Hyperglycemia was defined 
as non-fasting blood glucose >200 mg/dl.
experimental Protocol
Twenty age-matched mice were randomly assigned into two 
groups (10 animals per group). Group I served as control and 
received daily i.p. injection of sterile saline for 3 weeks. Group 
II mice received daily injection of paraoxon for 3  weeks. Mice 
were weighed weekly, at which time blood was also collected and 
analyzed for AChE activity. At the end of treatment, each group 
was divided randomly into two subgroups, A and B. Groups IA 
(Saline) and IIA (paraoxon) received daily injections of citrate 
buffer while groups IB (Saline/STZ) and IIB (paraoxon/STZ) 
received daily injection of STZ for five consecutive days. Pancreas, 
spleen, and serum were collected from mice sacrificed (ether 
exposure) at days 10 and 18, post-STZ administration. In some 
experiments, mice were followed for survival for up to 60 days.
ache activity of red Blood cells
The detailed procedure for determining AChE enzyme activ-
ity in red blood cells (RBC) has been described (36). Briefly, 
freshly drawn, diluted, venous blood samples were incubated 
with DTNB (10  mM) and ethopropazine (6  mM) for 20  min 
at 37°C prior to addition of acetylthiocholine. The change in 
the absorbance of DTNB was measured at 436 nm. The AChE 
activity was calculated using an absorption coefficient of TNB− at 
436 nm (ε = 10.6 mM−1 cm1). The values were normalized to the 
hemoglobin (Hb) content (determined as cyanmethemoglobin) 
and expressed as mU/μM/Hb (37). All enzyme activities were 
expressed as percentage of the baseline activity (100%).
histology and immunohistochemistry of 
Pancreatic Tissue
Excised pancreata were processed for histological analysis follow-
ing established protocol (38, 39). Tissue sections were stained with 
hematoxylin and eosin (H&E), and images were captured using 
Olympus BX53 microscope equipped with digital camera DP26 
(Tokyo, Japan). Indirect immunostaining for insulin was per-
formed using guinea pig polyclonal antibody (Dako, Carpinteria, 
CA, USA) followed by FITC-conjugated donkey anti-guinea pig 
IgG (Jackson ImmunoResearch, West Grove, PA, USA). A three-
step staining protocol was utilized to detect infiltrating T cells and 
macrophages. For T lymphocytes, CD3-specific rabbit polyclonal 
Ab (Dako) was used followed by biotinylated sheep anti-rabbit 
Ig (AbD Serotec, Hercules, CA, USA) and finally streptavidin-
FITC (eBioscience, San Diego, CA, USA). For macrophages, we 
used rat F4/80 mAb (BMA Biomedicals, Switzerland) followed 
by streptavidin-HRP and DAB (Dako). Slides with fluorescence 
were counter-stained with propidium iodide (BD Biosciences, 
USA) and then examined and photographed under a Nikon C1 
laser scanning confocal microscope. Slides stained with DAB 
were counter-stained with hematoxylin and visualized and pho-
tographed with an Olympus BX53. Histological quantification of 
CD3+ and F4/80+ cells was done on two to four non-consecutive 
sections per animal and using four to five mice per experimental 
group. All islets found in each section were included in the quan-
tification, which was carried out in a blinded fashion.
antibodies and Flowcytometry
Analysis of spleen cells was carried out using a multi-color FACS 
analysis, following a standard procedure (39, 40). Cells were 
stained with a combination of directly conjugated mAbs, washed, 
and analyzed using FACSCanto II (BD Biosciences, San Jose, CA, 
USA). The antibodies used were CD3-FITC, CD4-APC, and CD8-
APC-Cy7 (Biolegend, San Diego, CA, USA), CD19-PE-Cy7 and 
CD11c-PE (eBioscience), and CD11b-PE-Cy7 (BD Biosciences). 
Non-viable cells staining positive with 7AAD dye (eBioscience) 
were excluded from the analysis. Data collected on 50,000 cells 
were analyzed using FACSDiva software (BD Biosciences).
intracellular cytokine analysis
Spleen single cell suspensions were prepared and 2 × 106 cells/ml 
were seeded in 24 well plates and stimulated with PMA (100 ng/
ml)/Ionomycin (1 μg/ml) for 4 h at 37°C in the presence of bre-
feldin A (GolgiPlug; BDcytofix/cytoperm plusTM solution kit, BD 
Biosciences). After stimulation, cells were first stained with CD4-
APC and CD8-APC-Cy7 antibodies (Biolegend), resuspended 
in fixation/permeabilization solution and finally stained with 
anti-IL-17A-PE and anti-IFNγ-PE-Cy7 antibodies (eBioscience) 
and run using FACSCanto II (BD Biosciences). Data collected 
from 50,000 cells were analyzed using FACSDiva software (BD 
Biosciences).
Quantitative rT-Pcr
qRT-PCR was carried out as previously described (40) on RNA 
extracted from spleen and pancreas from each animal. After RNA 
extraction and purification, cDNA was synthesized using Taqman 
reverse transcription reagents (Applied Biosystems, Foster City, 
CA, USA) following manufacturer’s protocol. TaqMan primers 
and probes were used to study the expression of the inflamma-
tory markers IL-1β, IL-6, IL-12p40, IL-17A, IFNγ, and insulin 
(Applied Biosystems), and IL-23 and TNFα (Metabion, Germany) 
(Table  1). Transcript levels of target genes were normalized 
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according to the dCq method to respective mRNA levels of the 
housekeeping gene HPRT.
insulin and cytokine Determination
Serum samples were assayed for insulin (Alpco diagnostics, Salem, 
NH, USA) level by sandwich ELISA and performed according to 
the manufacturer’s instructions. Assay sensitivity was 188 pg/ml.
statistical analysis
Statistical significance between control and treated groups was 
analyzed using the unpaired, two-tailed Student’s t-test, using 
the statistical program of GraphPad Prism version 6 software. 
For multiple comparisons, we used One-way ANOVA with 
post hoc Tukey’s test (GraphPad Prism). Two-way ANOVA with 
Bonferroni post-test was used to analyze repeated measures data, 
as indicated. Survival analysis was performed by Kaplan–Meier 
survival curves and log-rank test, using the same GraphPad 
Prism program. Differences between experimental groups were 
considered significant when p values were <0.05.
resUlTs
MlD-sTZ-induced hyperglycemia
Studies were first carried out to optimize the STZ dose necessary 
to induce hyperglycemia (blood glucose >200 mg/dl) in C57BL/6 
mice. Animals were divided into three groups, each receiving 
either 40, 50, or 60 mg/kg dose of STZ for five consecutive days. 
As can be seen, the percentage of mice developing hyperglyce-
mia was 0, 50, and 100% by day 21 post administration of STZ 
at 40, 50, or 60 mg/kg, respectively (Image 1 in Supplementary 
Material). Hence, for all subsequent studies, a dose of 60 mg/kg 
STZ was used.
acetylcholinesterase inhibition Prevents 
hyperglycemia and Preserves insulin 
Production
In order to investigate the potential effect of AChE inhibition on 
experimental diabetes, C57BL/6 mice were pretreated daily with 
paraoxon or saline for 3  weeks, and then given MLD-STZ (or 
saline), as described in the Section “Materials and Methods” and 
followed for the development of hyperglycemia. No changes in 
glucose levels were observed in control mice (saline or paraoxon 
only experimental groups) (Figure 1A). Saline-pretreated mice 
that received STZ developed progressive hyperglycemia, first 
evident at 7 days post-STZ administration, and that continued 
for up to 51 days (Figures 1A,B). All animals in this group were 
diabetic by day 18 post STZ administration (Figure  1B). In 
contrast, despite an initial mild elevation in blood glucose levels 
observed at day 7, mice pretreated with paraoxon prior to STZ 
were resistant to the development of hyperglycemia (Figure 1B). 
This remained evident for up to 51 days following STZ adminis-
tration, the maximum period of observation (Figure 1B).
Serum insulin levels were determined on day 10 (Figure 1C) 
and 18 (Figure 1D) post STZ injection. Similar levels of serum 
insulin were observed in saline- and paraoxon-treated control 
mice at both time points (Figures  1C,D). Interestingly, for 
STZ-treated mice, while serum insulin was at normal level at day 
10 post administration (Figure  1C), the level dropped signifi-
cantly by day 18 to ~64% of control (Figure 1D). In contrast, no 
reduction in serum insulin was observed in mice pretreated with 
paraoxon followed by STZ (Figure 1D). The levels of serum insu-
lin of paraoxon/STZ-treated mice tended to be higher than saline 
control at days 10 and 18 post STZ injection (2.6-fold and 1.6-fold 
increase, respectively; Figures  1C,D) with the difference being 
statistically significant at the latter date. Moreover, differences 
in serum insulin levels between saline/STZ and paraoxon/STZ 
groups at day 18 were highly significant and inversely correlated 
with serum glucose levels (compare Figures 1A,D).
Insulin mRNA expression was also analyzed in pancreatic 
tissue at day 18 post-STZ treatment (Figure 1E). A dramatic 
10.6-fold increase in insulin expression was observed in par-
aoxon-treated mice compared with saline control (Figure 1E). 
In sharp contrast, STZ treatment (saline/STZ group) led to 
a 12-fold reduction in the level of insulin mRNA relative to 
saline control. In mice pretreated with paraoxon prior to STZ 
(paraoxon/STZ group), insulin mRNA levels were essentially 
similar to those observed in saline control group (Figure 1E). 
Immunohistochemical analysis of insulin-producing β cells in 
pancreatic tissue revealed a gradual loss of insulin positivity 
in STZ-treated mice (saline/STZ group), which was evident 
starting at day 10 following STZ administration and continued 
up to day 60 (Figure  1F). In contrast, mice pretreated with 
paraoxon (paraoxon/STZ group) showed evidence of islet 
preservation and protection from STZ-induced loss of β cells, 
albeit not total, up to day 60 (Figure 1F). These results dem-
onstrate that inhibition of AChE increases the expression of 
insulin mRNA in pancreatic cells and prevents STZ-induced 
hyperglycemia.
inhibition of ache Prevents insulitis and 
Destruction of islets induced by MlD-sTZ
Hematoxylin and eosin staining of pancreatic tissue showed 
highly infiltrated islets in saline/STZ group at days 10 and 
18 post-STZ administration (Figure  2A). Pretreatment with 
paraoxon reduced islet cell infiltration at day 10 (paraoxon/STZ 
group) and, by day 18, the pancreatic islets appeared completely 
healthy with no evidence of insulitis (Figure 2A). No infiltrating 
cells were observed in islets of saline or paraoxon control groups 
(Figures 2A–E). Immunohistological analysis of the islets at days 
10 and 18 revealed the presence of CD3+ T cells (Figure 2B) and 
F4/80+ myeloid cells (Figure 2C) in STZ-treated mice. However, 
the degree of T cell infiltration was significantly reduced in mice 
pretreated with paraoxon (Figures  2B,D). At day 10, T cells 
were distributed uniformly throughout the islets of both saline/
STZ and paraoxon/STZ groups. At day 18, however, only a few 
T cells located primarily in the periphery of the islets could be 
observed in paraoxon/STZ mice, while in saline/STZ group these 
cells were uniformly distributed within the islets (Figure  2B). 
Administration of STZ also induced a significant increase in 
intra-islet recruitment of macrophages, regardless of the pretreat-
ment received (Figures  2C,E). No significant differences were 
found between saline and paraoxon control groups (Figure 2E).
FigUre 1 | administration of ache inhibitor modulates the development of sTZ-induced diabetes. C57BL/6 mice pretreated with paraoxon (Pox) or 
Saline for 3 weeks were challenged with 60 mg/kg/day of STZ for five consecutive days. (a) Blood glucose concentrations in tail blood samples were measured at 
indicated time points. Mice with blood glucose measurements >200 mg/dl were considered diabetic. Data are pooled from three independent experiments and the 
total number of mice is shown in parenthesis for each group. Two-way ANOVA with Bonferroni post-test was used for statistical analysis. (B) Percentage of diabetic 
animals in mice pretreated with saline or paraoxon followed by MLD-STZ challenge over an observation period of 51 days. Data are pooled from six independent 
experiments (22–25 mice per group up to day 18 post-STZ and 9 mice per group for later time points). (c,D) Serum insulin levels were determined at day 10 (c) 
and day 18 (D) post-STZ administration. (e) mRNA expression of pancreatic insulin in mice sacrificed at day 18 post-STZ treatment. Each data point represents the 
mean ± SEM of the values obtained from four to six animals per group. Student’s t-test was used for graphs (c–e). Asterisks above bars denote statistically 
significant differences between the indicated experimental groups and saline-control group. Asterisks above brackets denote significance between the indicated 
experimental groups (*p < 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001). (F) Light confocal micrographs (×40) of pancreatic islets of C57BL/6 mice pretreated with 
saline/STZ or Pox/STZ showing immunofluorescence of insulin-containing β cells. Total follow-up period was 60 days. Photos are representative of two individual 
experiments (four mice/group/experiment). Bar in the figures indicates 25 μm.
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Next, we investigated mRNA expression of proinflammatory 
cytokines in pancreatic tissue at day 18 post-STZ (Figures 2F,G). 
STZ administration led to a significant increase (3.1-fold) in IFNγ 
mRNA expression compared with saline controls (Figure  2F). 
Interestingly, mice pretreated with paraoxon alone also exhibited 
a 2.4-fold increase in pancreatic IFNγ expression compared with 
controls. In contrast, mice pretreated with paraoxon followed by 
STZ showed similar levels of IFNγ expression to those receiving 
paraoxon alone (detectable in only 2/6 mice examined; Figure 2F). 
Expression of pancreatic IL-1β was also assessed in the different 
experimental groups. The highest level of IL-1β expression was 
observed in saline/STZ group (Figure  2G). In contrast, IL-1β 
expression levels dropped significantly in paraoxon (2.5-fold) and 
paraoxon/STZ (2.7-fold) experimental groups compared with 
saline/STZ group (Figure 2G). For pancreatic IL-23, expression 
was almost undetectable in saline and paraoxon groups, was max-
imal in saline/STZ group and decreased by >50% in paraoxon/
STZ-treated mice compared with saline/STZ group; however, this 
difference was not statistically significant (Figure 2H). Analysis 
of pancreatic TNFα expression revealed only background levels 
FigUre 2 | inhibition of ache reduces sTZ-mediated insulitis. (a) Representative images of H&E stained pancreatic islets from the four different experimental 
groups sacrificed at day 10 or 18 post-STZ administration. Arrows indicate infiltrating inflammatory cells (bar = 20 μm). (B,c) Pancreatic sections were stained with 
anti-CD3 (B) or F4/80 (c) antibodies, as described in Section “Materials and Methods” to detect T cells and macrophages, respectively. Dashed lines delineate 
pancreatic islets. Representative images (40×) from two independent experiments (four mice/group/experiment) are shown. Arrows indicate representative cells. 
Bars in the figures indicate 50 μm in CD3 staining and 20 μm in F4/80 staining. (D,e) Quantitative estimation of the number of T cells (D) and macrophages (e) per 
islet in pancreatic section of different treatment groups sacrificed at day 10 post-STZ administration. Data are shown as the mean ± SEM of the number of positive 
cells per high power field. (F–h) Relative expression levels of IFN-γ (F) and IL-1β (g) and IL-23p19 (h) mRNA, expressed as fold change compared to saline 
controls, isolated from pancreas of mice sacrificed day 18 post-STZ administration. Each data point represents the mean ± SEM of the values obtained in that 
group. Since cytokine expression was not detectable in every mouse of each group, the ratio of the animals positive for each cytokine is also shown. Fractions 
above the bars indicate the number of mice with positive value/total number of mice in the group. One-way ANOVA was used for statistical analysis in Figures A–E. 
Asterisks above bars denote statistically significant differences between the indicated experimental groups and saline-control group. Asterisks above brackets 
denote significance between the indicated experimental groups (*p < 0.05; **p ≤ 0.01; ***p ≤ 0.001).
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with no significant differences among the experimental groups 
(data not shown). Moreover, no cytokines could be detected 
in pancreatic tissue at day 10 post-STZ treatment in any of the 
groups (data not shown).
inhibition of ache reduced splenic 
Proinflammatory cytokines and Th17 
effector cells
Next, we explored the effect of AChE inhibition on the peripheral 
immune response in STZ-treated mice. Immunophenotyping 
revealed no gross differences in the percentage of major spleen 
cell populations among the four different experimental groups at 
either day 10 or 18 post STZ administration (Images 2 and 3 in 
Supplementary Material), the only exception being a small but 
significant decrease in the frequency of CD8+ T cells in the par-
aoxon/STZ group compared with saline/STZ-treated mice at day 
10 post-STZ administration (Images 2 and 3 in Supplementary 
Material). Given the role of IL-17 and Th17 cells in autoimmune 
diabetes and their counter regulation by IFNγ (27, 41), mRNA 
expression levels of IFNγ and IL-17 were determined in spleen 
cells. Moderate upregulation of IFNγ expression was observed in 
FigUre 3 | inhibition of ache suppresses sTZ-induced Th17 cells and promotes iFnγ-secreting Th1 differentiation. C57BL/6 mice pretreated with 
paraoxon (Pox)/Saline for 3 weeks were administered STZ/vehicle for five consecutive days and sacrificed 18 days later. (a–e) Relative mRNA expression levels of 
IFNγ (a), IL-17F (B), IL-6 (c), IL-23p19 (D), and IL-12p40 (e) isolated from whole spleen. Each value represents the mean ± SEM of data collected from three 
independent experiments (7–10 mice/group). One-way ANOVA was used for the statistical analysis for (a–e) graphs. Asterisks above bars denote statistically 
significant differences between the indicated experimental groups and saline-control group. Asterisks above brackets denote significance between the indicated 
experimental groups (*p < 0.05). (F–i) Intracellular cytokine analysis. Splenocytes were stimulated ex vivo with PMA/ionomycin and analyzed for CD4 and CD8 
positivity and IFNγ and IL-17 content. Each experimental group included three mice. (F) Representative results of individual mice are shown, and are representative 
of two independent experiments. Percentages of CD4+IFNγ+ (g), CD8+IFNγ+ (h), and CD4+IL-17A+ (i) T cells are depicted in the graphs. Values represent the 
mean ± SEM of six mice per group. Student’s t-test was used for data analysis of Figures G–I. Asterisks denote statistically significant differences between the 
indicated groups (*p < 0.05, **p ≤ 0.01).
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mice pretreated with AChE inhibitor (paraoxon and paraoxon/
STZ groups) compared with saline control (Figure  3A), with 
the differences being statistically significant between saline/STZ 
and paraoxon/STZ groups. Conversely, while administration of 
STZ led to a 4.7-fold increase in IL-17 expression compared with 
saline control animals (Figure 3B), pretreatment with paraoxon 
abrogated the IL-17 response (paraoxon/STZ group; Figure 3B). 
These results suggest that inhibition of AChE led to an increase in 
IFN-γ production and a reduction in STZ-induced IL-17. Further 
analysis revealed a reduction in the expression of IL-6 and IL-23, 
cytokines involved in the differentiation of Th17 cells, in groups 
receiving paraoxon compared with saline group (Figures 3C,D). 
Moreover, compared with control animals, IL-6 expression was 
upregulated in saline/STZ group (Figure 3C). On the other hand, 
expression levels of IL-12, an IFNγ-promoting cytokine, were 
found to be upregulated in paraoxon-treated groups compared 
with saline control (2.7-fold and 1.8-fold increase in paraoxon 
and paraoxon/STZ groups, respectively; Figure 3E). Significant 
differences in IL-12 expression were observed between paraoxon-
treated mice compared with the saline or saline/STZ group 
(Figure  3E). No significant differences were observed in the 
expression of TNFα and IL-1β proinflammatory cytokines among 
experimental groups (data not shown). These findings suggest 
that inhibition of AChE may prevent STZ-induced hyperglycemia 
by modulating the balance between Th1 and Th17 development.
To assess this directly, we determined the percentage of IL-17+ 
and IFNγ+ splenic T cells at day 18 post-STZ administration. Ex 
vivo stimulation with PMA/ionomycin followed by intracel-
lular cytokine staining revealed that pretreatment with paraoxon 
induced a moderate increase in the percentage of IFNγ+CD4+ 
FigUre 4 | iFnγ is required for amelioration of sTZ-induced hyperglycemia. Transient reduction in RBC-AChE activity in C57BL/6 (a) and IFNγ−/− (D) mice 
during the course of paraoxon administration. All enzyme activities are expressed as percentage of the baseline activity (100%). Blood glucose levels in C57BL/6 (B) 
and IFNγ−/− (e) mice were measured at indicated time points post STZ treatment. Changes in body weights in C57BL/6 (c) and IFNγ−/− (F) mice during paraoxon 
treatment and up to 42 days post-STZ administration. The mean values ± SEM are depicted in all graphs. Two-way ANOVA with Bonferroni post-test was used for 
the statistical analysis of (a–F). Asterisks denote statistically significant differences between the two groups at each time point (*p < 0.05, **p ≤ 0.01, ***p ≤ 0.001, 
****p ≤ 0.0001). (g) Survival was followed for up to 60 days after STZ administration. Kaplan–Meier and log-rank test was used for analysis. All results represent 
cumulative data of two independent experiments. Asterisks denote statistically significant differences between the indicated groups (*p < 0.05).
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cells (Figure 3F). Saline/STZ group exhibited significant reduc-
tion in percentage of IFNγ+CD4+ and IFNγ+CD8+, but increased 
percentage of IL-17+CD4+, T cells compared with paraoxon and 
paraoxon/STZ group (Figures 3F–I). Percentage of CD4+IL-17+ 
cells in saline/STZ group was significantly increased compared 
with paraoxon-treated groups (2.4-fold and 2-fold that of par-
aoxon and paraoxon/STZ groups, respectively) (Figures  3F,I). 
Expression of IL-17 was detected mainly in CD4+, but not CD8+ 
T cells (Figure 3F). These results support the idea that inhibition 
of AChE leads to a preferential induction of a Th1 response that 
suppresses STZ-driven Th17 cell differentiation.
inhibition of ache Fails to Prevent sTZ-
induced hyperglycemia in iFnγ−/− Mice
To further elucidate the role of IFNγ in the development of hyper-
glycemia, we utilized the same MLD-STZ model to induce diabetes 
in IFNγ−/− mice. Administration of paraoxon induced 50–60% 
inhibition in AChE activity in both wild-type (WT) C57BL/6 as 
well as IFNγ−/− mice (Figures 4A,D). Importantly, pretreatment 
with paraoxon protected against STZ-triggered hyperglycemia in 
WT (Figure 4B) but not in IFNγ−/− mice (Figure 4E). WT mice 
developed hyperglycemia 7–10 days post STZ administration and 
this continued up to 7 weeks later (Figure 4B). In contrast, no 
hyperglycemia was observed in paraoxon-pretreated WT mice 
after STZ injection (Figure 4B). It is intriguing to point out that 
paraoxon pretreatment in IFNγ−/− mice did appear to protect 
against onset of hyperglycemia during the first 10 days follow-
ing STZ administration (Figure  4E). Subsequently, however, 
paraoxon-pretreated IFNγ−/− mice became hyperglycemic and, 
by day 49, their blood glucose levels reached 500 mg/dl, identi-
cal to saline-pretreated mice (Figure 4E). A moderate degree of 
weight loss (10–15%) is commonly observed in mice treated with 
AChE inhibitors (36, 42), and this was observed in both WT and 
FigUre 5 | inhibition of ache fails to prevent the loss of insulin-producing β cells induced by sTZ administration in iFnγ−/− mice. IFNγ−/− mice treated 
with paraoxon (Pox) or Saline for 3 weeks were challenged with 60 mg/kg/day of STZ for five consecutive days. (a) Light confocal micrographs (40×) of pancreatic 
islets from IFNγ−/− mice from different experimental groups at days 10 and 18 post-STZ, showing immunofluorescence to insulin-containing β cells. Photos are 
representative of two individual experiments (four mice/group/experiment). Bar in the figures indicates 25 μm. (B) Serum insulin levels were determined at day 10 
and 18 post-STZ administration. Student’s t-test was used for the statistical analysis. Asterisks denote statistically significant differences between experimental 
groups (*p < 0.05).
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IFNγ−/− mice particularly during the 3-week (day –21 to day 0) 
paraoxon pretreatment period (Figures 4C,F). Following the end 
of paraoxon pretreatment period, the animals’ weights gradually 
normalized and by day 28 were identical to saline-pretreated 
mice (Figures 4C,F). As WT mice developed hyperglycemia due 
to STZ, they begin to loose weight and this was clearly evident 
by day 35 post STZ injection (Figure 4C). However, paraoxon-
pretreated WT mice exhibited no further loss of weight after STZ 
and, in fact, their weights were higher than saline/STZ group 
at days 35 and 42 post STZ (Figure 4C). In contrast, although 
IFNγ−/− mice also recovered their initial weight after paraoxon 
treatment, they did not exhibit further weight gain after STZ 
administration due to their hyperglycemic state (Figures 4E,F). 
Finally, we also assessed long term survival in STZ-injected mice 
(C57BL/6 and IFNγ−/−) following pretreatment with either saline 
or paraoxon (Figure 4G). Irrespective of the treatment, no deaths 
were recorded in C57BL/6 mice up to 60 days post STZ admin-
istration. In sharp contrast, only about 20% of IFNγ−/− mice, 
whether pretreated with saline or paraoxon, survived by day 60 
post-STZ (Figure 4G). This is most likely due to the higher levels 
of hyperglycemia observed in these mice (Figure 4E). These find-
ings confirm the important role that IFNγ plays in cholinergic 
pathway-mediated inhibition of diabetes development in the 
MLD-STZ model.
ache inhibition Does not Prevent sTZ-
Mediated islet β cell Damage in iFnγ−/− 
Mice
Next, we analyzed the status of insulin-producing cells in 
pancreatic tissue of IFNγ−/− mice at days 10 and 18 post STZ 
administration. Compared with saline controls, saline/STZ group 
showed a reduction in insulin-producing β cells by day 10 post 
STZ injection, and this became more pronounced at day 18 post 
STZ (Figure 5A). Pretreatment with paraoxon appeared to delay 
the loss of insulin-positive β cells. Moreover, paraoxon-treated 
FigUre 6 | in iFnγ−/− mice, inhibition of ache does not prevent sTZ-induced insulitis. (a) Paraffin embedded pancreata from the four different experimental 
groups, sacrificed at day 10 or 18 post-STZ administration, were sectioned and stained with H&E. Representative images are shown where arrows indicate 
infiltrating inflammatory cells (bar = 20 μm). Pancreatic sections were also stained with anti-CD3 (B) or F4/80 (c) antibodies, as described in Section “Materials and 
Methods” to detect T cells and macrophages, respectively. Dashed lines delineate pancreatic islets. Representative images (40×) from two independent experiments 
(four mice/group/experiment) are shown. Arrows indicate representative cells. Bars in the figures indicate 50 μm in CD3 staining and 20 μm in F4/80 staining. 
Quantitative estimation of the number of T cells (D) and macrophages (e) per islet in pancreatic section of different treatment groups sacrificed at day 10 post-STZ 
administration. Data are shown as the mean ± SEM of the number of positive cells per high power field. One-way ANOVA was used for the statistical analysis (D,e). 
Asterisks above bars denote statistically significant differences between the indicated experimental groups and saline-control group. Asterisks above brackets 
denote significance between the indicated experimental groups (*p < 0.05).
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IFNγ−/− mice exhibited higher levels of serum insulin compared 
with saline control (Figure 5B; paraoxon group). No reduction 
in serum insulin was observed in paraoxon/STZ-treated mice 
during the first 10  days post-STZ administration (paraoxon/
STZ group). However, by day 18, serum insulin levels dropped to 
become similar to the ones in the saline/STZ group (Figure 5B). 
These data suggest that IFNγ does not play a role in the initial 
control of STZ-induced hyperglycemia.
Hematoxylin and eosin staining of pancreatic tissue of 
IFNγ−/− mice showed highly infiltrated islets in the saline/STZ 
group at day 10 and 18 post STZ administration (Figure 6A; left 
middle and bottom panels). In contrast, pancreatic islets from 
paraoxon/STZ group exhibited mild infiltration at day 10, but by 
day 18 all islets appeared infiltrated although to a lesser extent 
than in saline/STZ group (Figure 6A; right middle and bottom 
panels). No apparent cell infiltration could be observed in islets 
of saline or paraoxon control groups (Figure  6A; top panels). 
Immunohistological analysis of the islets at day 10 and 18 revealed 
the presence of fewer CD3+ T cells than in WT mice, with high-
est levels being detected in saline/STZ group (Figures  6B,D). 
Pretreatment with paraoxon reduced by >60% the extent of T 
cell infiltration (paraoxon/STZ group) compared to saline/STZ 
group (Figure 6D). Staining with F4/80 mAb revealed a similar 
extent of macrophage infiltration in all four experimental groups 
(Figures 6C,E).
inhibition of ache leads to a Partial 
alteration in Th17 cell ratio in the 
absence of iFnγ
As expected, intracellular staining of splenocytes of IFNγ−/− mice 
showed no CD4+IFNγ+ or CD8+IFNγ+ T cells (Figure 7A). AChE 
inhibition induced a partial but not statistically significant reduc-
tion in the percentage of CD4+IL-17+ cells (paraoxon group). STZ 
FigUre 7 | inhibition of ache in the absence of iFnγ production leads to a partial decrease in Th17 differentiation. IFNγ−/− mice treated with paraoxon 
(Pox) or Saline for 3 weeks were administered STZ or vehicle for five consecutive days and sacrificed 18 days later. Spleens were obtained and single cell 
suspensions prepared. Splenocytes were stimulated with PMA/ionomycin and analyzed for CD4/CD8 positivity and IFNγ/IL-17 content (a). Each experimental group 
included three mice. Results of individual mice are shown and are representative of two independent experiments. (B) Percentages of CD4+IL-17A+ T cells are 
depicted. Values represent the mean ± SEM of three mice per group. Data analysis was done by Student’s t-test. Asterisks above bars denote statistically significant 
differences between the indicated experimental groups and saline-control group. Asterisks above brackets denote significance between the indicated experimental 
groups (*p < 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001).
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administration induced the differentiation of CD4+IL-17+ cells 
in saline/STZ group (mean ± SEM = 3.7 ± 0.2%; Figures 7A,B) 
which represents a 2.9-fold increase in comparison to saline 
controls. For paraoxon/STZ-treated mice, the percentage 
of CD4+IL-17+ cells was slightly, but significantly, reduced 
(2.3 ± 0.2%) compared to saline/STZ group but was still signifi-
cantly higher than that of saline and acetylcholinesterase inhibi-
tor (AChEI) groups (Figures 7A,B). Nevertheless, the presence 
of a significant level of CD4+IL-17+ T cells in paraoxon/STZ-
treated IFNγ−/− mice is in sharp contrast to the findings in WT 
mice where similar treatment reduced the ratio of CD4+IL-17+ 
T cells to background levels (Figure 3F). These results highlight 
the immunomodulatory effect of the cholinergic pathway and 
the important role of IFNγ in preventing the development of 
STZ-induced diabetes.
DiscUssiOn
Several studies have revealed the importance of the parasympa-
thetic nervous system in regulating immune responses in infec-
tious (9, 11) as well as autoimmune disease models (15, 22). The 
purpose of this study was to explore the effect of AChE inhibition 
on the onset and development of T1D induced by MLD-STZ 
administration. Cholinergic stimulation was induced through 
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the utilization of an irreversible specific inhibitor of AChE, the 
primary ACh-hydrolyzing enzyme, thus leading to increased 
ACh levels. The findings of the current study demonstrate four 
main points. First, prophylactic cholinergic stimulation inhibits 
development of STZ-mediated hyperglycemia and T1D. Second, 
this is achieved by direct enhancement of insulin production 
by pancreatic β cells and by protecting these cells against STZ-
induced autoimmune, cytotoxic damage. Third, ACh induces 
a shift in MLD/STZ-triggered T cell differentiation away from 
pathogenic IL-17-secreting Th17 cells to IFN-γ-secreting Th1 
cells. Finally, ACh-mediated protection is significantly attenuated 
in mice deficient in IFNγ synthesis, providing strong evidence 
for the critical role of this cytokine in the response to cholinergic 
pathway activation in this autoimmune model.
The vagus nerve innervates the pancreas and controls both 
endocrine and exocrine secretions (43, 44). Secretion of ACh 
via vagus nerve stimulation acts on mAChRs expressed on β 
cells and upregulates the production of insulin (45–48). Our 
results showing that inhibition of AChE induced an increase in 
pancreatic insulin mRNA expression are consistent with these 
previous findings. The induced increase in insulin synthesis 
could compensate for the damage triggered by STZ and prevent 
the initial development of hyperglycemia. Moreover, it has been 
shown that STZ treatment upregulated the expression of pan-
creatic AChE, which in turn induced the death of islet cells (49). 
Therefore, the prophylactic inhibition of AChE could prevent 
STZ-induced destruction of β cells and preserve the production 
of insulin.
A recent study reported that inhibition of AChE by gal-
antamine delayed the onset of diabetes in NOD mice (50). 
Moreover, we have preliminary evidence that other AChE 
inhibitors, such as galantamine and rivastigmine, also prevent 
the development of hyperglycemia in the MLD-STZ model (data 
not shown). Increased cholinergic activity through vagus nerve 
stimulation also plays an important role in suppressing pancre-
atic inflammation (51). Previously, we and others reported that 
peripheral administration of an AChE inhibitor resulted in pro-
tective anti-inflammatory manifestations at both the mucosal 
as well as systemic levels (11, 52). Herein, our results show that 
inhibition of AChE in STZ-treated mice leads to reduced islet 
infiltration by CD3+ T cells and significantly lower levels of 
pancreatic IL-1β and splenic IL-6 and IL-17 mRNA expression. 
Therefore, our data suggest that cholinergic pathway activation 
influences the development of hyperglycemia in the MLD-STZ 
model by acting at both local (pancreas) and systemic immune 
system levels.
IFNγ was initially considered the cytokine responsible for the 
pathogenesis of autoimmune diabetes (53, 54). This view changed 
with the demonstration that IFNγ-deficient NOD mice were still 
susceptible to insulitis and diabetes, albeit with delayed onset (55). 
Moreover, splenocytes from diabetic IFNγ−/− NOD mice could 
fully transfer disease to naïve mice, suggesting the involvement 
of other T cell subpopulations. Th-17 cells have been described 
as potent inducers of autoimmune tissue inflammation. An 
expansion of pathogenic Th17 cells and excess IL-17 production 
have been implicated in murine and human T1D (24, 25, 31, 32) 
and other autoimmune diseases (56, 57). In STZ-induced T1D, 
mice deficient in IL-17R (28) or IL-17 (29) are resistant to STZ-
induced diabetes progression and exhibit reduced insulitis and 
hyperglycemia, indicating that IL-17 plays a pathogenic role in 
this model. In the NOD mouse model, inhibition of Th17/IL-17 
suppressed the development of diabetes (24, 25). The interplay 
between Th17 and Th1 at the effector phase appears to be a criti-
cal determinant of disease onset and progression. In the present 
study, we demonstrate that inhibition of AChE upregulates IFNγ 
synthesis in the pancreas and spleen and increases the frequency 
of IFNγ-positive Th1 cells. Taken together with the findings show-
ing reduced expression of IL-6 and IL-1β, two cytokines involved 
in the differentiation of Th17 from memory cells (58), cholinergic 
pathway-induced immunomodulatory effects led to a reduction 
in the ratio of IL-17-producing Th17 cells and IL-17 cytokine 
levels in treated mice. These findings suggest an important role 
for the cholinergic pathway in regulating the development of 
autoimmune diabetes.
The spleen is a major secondary lymphoid organ where antigen 
presentation, T cell activation and clonal expansion can take place. 
It is known that the vagus nerve does not innervate the spleen 
directly. Instead, the vagus nerve terminates in the celiac ganglion 
from which the adrenergic splenic nerve projects, innervating the 
spleen through the release of noradrenaline. Within the spleen, 
noradrenaline acts on a subset of memory T cells and stimulate 
the release of ACh from these cells (59). Our data demonstrate 
that inhibition of AChE reduced the expression of splenic IL-6 
and IL-23, two cytokines with critical roles in Th17 development 
and pathogenicity (60), and upregulated expression of IL-12 and 
IFNγ. IL-12 is an important immunoregulatory cytokine, being 
a potent inducer of IFNγ while inhibiting the production of IL-6 
and IL-23 (35, 61). Increasing evidence suggests that IFNγ has 
modulatory effects on immune cells, including IL-17-producing 
Th17 cells. The development of Th17 cells from naïve cells is 
potently inhibited by IFNγ and IL-4 (27, 62). The presence 
of higher levels of IFNγ in the spleen would interfere with the 
differentiation of naïve T cells into Th17 cells (63), reducing the 
availability of pathogenic Th17 cells to migrate to the pancreas. 
Our findings are consistent with earlier studies suggesting an 
inhibitory role for IFNγ in the development of Th17 cells and 
T1D in NOD mice (24, 27). At the level of target tissue (pancreas), 
inhibition of AChE led to a reduction in IL-1β and IFNγ expres-
sion, two proinflammatory cytokines known to induce apoptosis 
in the pancreatic β cells (64). These findings support the idea that 
IFNγ in diabetes may have dual functionalities, a pathogenic 
role at the level of pancreas and a protective role at the level of 
spleen (24).
A few studies have addressed the direct effect of cholinergic 
stimulation on isolated immune cell populations. Nicotine, a cho-
linergic agonist of nAChR, was shown to increase the production 
of IL-12 by macrophages and DCs in vitro (65, 66). Both mAChR 
and nAChR are known to be expressed on T cells, with muscarinic 
stimulation leading to enhanced IL-10 and IL-17 production 
while nicotinergic stimulation upregulating IFNγ and inhibiting 
IL-17 (67). Therefore, cholinergic stimulation could act directly 
on T cells to stimulate IFNγ production or indirectly through DCs 
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and macrophages increasing the production of IL-12. The fact 
that we observed a partial reduction in  IL-17-expressing CD4+ T 
cells in paraoxon/STZ-treated IFNγ−/− mice suggests that IL-12 
could regulate Th17 activation independent of IFNγ. In addi-
tion to Th17 cells, IL-17-producing CD8+ T cells (Tc17) are also 
induced in the MLD-STZ diabetes model (28). Interestingly, the 
increased frequency of Tc17 cells was only evident early after STZ 
administration (day 6) but normalized by day 11 post-STZ (28). 
In our current study, we could not detect any significant presence 
of Tc17 cells in any of the experimental groups, most likely due 
the earliest time point being at day 10 post STZ. Nevertheless, a 
small but significant decrease in total CD8+ T cells was noted at 
day 10 in paraoxon/STZ-treated mice in comparison to the saline/
STZ group (Image 2 in Supplementary Material). Therefore, it 
is possible that administration of AChE inhibitors could also 
influence disease development by preventing the activation and 
differentiation of CD8+ T cells and Tc17 cells. Furthermore, there 
is evidence suggesting that IL-12 could enhance the suppressive 
activity of Tregs, thereby contributing indirectly to the control of 
pathogenic autoimmune T cells (68). Further studies are needed 
to investigate the exact mechanism by which AChE inhibition 
mitigates against the development of pathogenic Th17 cells in 
autoimmune diabetes.
In conclusion, the findings in the present report demonstrate 
that inhibition of AChE reduces the incidence of STZ-induced 
T1D and provides, for the first time, mechanistic evidence that 
this is achieved through the inhibition of pathogenic Th17 cells. 
Furthermore, the data demonstrate a pivotal role for IFNγ in 
mediating the observed protective effect. The possibility of 
modulating disease severity by therapeutic administration of 
AChE inhibitors is currently under investigation. Taken together, 
these results suggest a promising strategy for preventing T1D and 
other autoimmune diseases.
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